DOPAMINE AGONISTS AND METOCLOPRAMIDE
Centrally-acting dopamine antagonists (such as metoclopramide) are expected to oppose the effects of the dopamine agonists. Metoclopramide would also be expected to reduce the prolactin-lowering effect of bromocriptine.
Concurrent use should be avoided, or monitored closely to ensure that the dopamine agonist remains effective. Domperidone is the antiemetic of choice in Parkinson's disease.
Concurrent use should be avoided, or monitored closely to ensure that the dopamine agonist remains effective. Domperidone is the antiemetic of choice in Parkinson's disease.